Biovica: Q2 outlook - Redeye

Biovica has secured the SEK 140m new funds in growth capital and the US commercial team is also in place. The company is now preparing for the US launch and the CLIA certification is expected to be secured during Q1 as a result of a FDA visit in January. The next major step in the US launch is the ability to establish an early interest from leading centers and significant hospitals during H1 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/868953/biovica-q2-outlook?utm_source=finwire&utm_medium=RSS